At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Atorvastatin +1 moredrug
Likely dose
Atorvastatin 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC)
In Brief
A Phase 2 clinical trial evaluating Atorvastatin and Placebo for Cerebral Cavernous Malformation. Completed, enrolled 80 participants across 1 site.
Detailed Summary
This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by validated quantitative susceptibility mapping (QSM) MRI studies in patients who suffered a symptomatic bleed within the preceding one year.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Cavernous Malformation
CountriesUnited States
CollaboratorsJohns Hopkins University
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartJul 2018
Primary CompletionJul 2024
Study CompletionMar 2025
TodayJul 2026
First PostedNov 11, 2015
Enrollment StartJul 17, 2018
Primary CompletionJul 31, 2024
Study CompletionMar 31, 2025
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 10.6 years ago
Interventions
Atorvastatindrug
40-80 mg OD
Placeboother
inactive